Merck & Co. (MRK)
(Delayed Data from NYSE)
$130.23 USD
+0.68 (0.52%)
Updated May 9, 2024 04:00 PM ET
After-Market: $130.27 +0.04 (0.03%) 4:54 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MRK 130.23 +0.68(0.52%)
Will MRK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
A Look at Pharma ETFs Post Q1 Earnings
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Here's Why Merck (MRK) is a Strong Momentum Stock
Here's Why Merck (MRK) is a Strong Momentum Stock
Other News for MRK
June 28th Options Now Available For Merck (MRK)
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
Merck says Keytruda failed as first-line therapy for uterine cancer
Merck provides update on Phase 3 KEYNOTE-B21 trial